Trump Says Anthropic No Longer Seen as National Security Threat 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
BHP Shares Fall as Jansen Potash Project Costs Surge 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
AMSTERDAM, the Netherlands, Jan. 6, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press release at 06:00 EST/12:00 CET on January 7, 2016. The Company's management team will hold a conference call and webcast at 08:30 EST/14:30 CET after the press release has been issued to discuss the update.
The conference call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code: 1640435. The webcast, including accompanying slides also available as a PDF file, can be accessed through the link displayed in the "Events" section on the "Media" page of the uniQure website at http://www.uniqure.com/news/calendar-of-events/. The webcast replay will be available for at least 72 hours following the call.
Conference Call Numbers
| London, United Kingdom: | +44 (0) 20 3427 1906 | |
| New York, United States of America: | +1 212 444 0412 | |
| Berlin, Germany: | +49 (0) 30 3001 90534 | |
| Amsterdam, Netherlands: | +31 (0) 20 716 8296 | |
| Paris, France: | +33 (0) 1 76 77 22 31 | |
| Milan, Italy: | +39 02 3859 1420 | |
| Brussels, Belgium: | +32 (0) 2 402 3092 | |
| Montreal, Canada: | +1 514 841 2154 | |
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Direct: +31 20 240 6110
Main: +31 20 240 6000
[email protected]
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or
+1 781 235 3060
[email protected]
